CRISPR is now one of the most affordable forms of gene editing causing a boom in R&D over the last few years. However, the technique does have its limitations which include maintaining end to end control on genetic manipulation, avoiding off targets effects and pathway recovery post double strand break.
Ahead of the 2017 CRISPR summit Javier Terriente, CSO, ZeClinics and Danilo Maddalo Lab Head ONC Pharmacology, Novartis Institutes for BioMedical Research discuss the latest regarding CRISPR delivery challenges and applications within Pharma.
Experts
| |
Danilo Maddalo |
| Have Your Say Rate this feature and give us your feedback in the comments section below |